Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 170

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 170
---
 with SEC filings, including consents and comfort letters.

Audit
Committee Pre-Approval Policy and Procedures

On
a periodic basis, the Audit Committee reviews and generally pre-approves the services (and related fee levels or budgeted amounts) that
may be provided by Haskell & White LLP without first obtaining specific pre-approval from the Audit Committee. The Audit Committee
may revise the list of general pre-approved services from time to time, based on subsequent determinations. Our Audit Committee pre-approves
all audit, review, and attest services proposed to be performed by our independent auditor that have not been generally pre-approved,
including the scope of services to be performed and the compensation to be paid to the auditor, prior to commencement of such engagements
of the independent auditor. Our Audit Committee has authorized all auditing and non-auditing services provided by Haskell & White
LLP during the fiscal year ended December 31, 2024 and the fees paid for such services.

PART
IV

Item
15. Exhibits and Financial Statement Schedules.

(a)(1)
Financial Statements.

The
financial statements required by this item are listed in Item 8. “Financial Statements and Supplementary Data” in this Annual
Report.

(a)(2)
Financial Statement Schedules.

The
financial statement schedules are omitted because they are either not applicable or the information required is presented in the financial
statements and notes thereto under Item 8. “Financial Statements and Supplementary Data” in this Annual Report.

(a)(3)
Exhibits.

The
following is a list of exhibits filed as part of this Annual Report.

94

Exhibit
Index

    Exhibit
    No.
     
    Exhibit
    Description
  
    2.1++
     
    Agreement and Plan of Merger and Reorganization, dated as of March 15, 2021, by and among Intec Pharma Ltd., Intec Parent, Inc., Dillon Merger Sub Inc., Domestication Merger Sub Ltd., and Decoy Biosystems, Inc. (incorporated herein by reference to Exhibit 2.1 to Intec Israel’s Report on Form 8-K filed with the SEC on March 15, 2021)
  
    2.2
     
    Agreement and Plan of Merger, dated as of April 27, 2021, by and among Intec Pharma Ltd., Intec Parent, Inc. and Domestication Merger Sub Ltd. (incorporated herein by reference to Exhibit 2